MDD Treatment: Augment or Switch
Expert Advice on MDD Treatment: When to Augment or Switch

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: January 01, 2025

Expiration: April 16, 2025

About This Tool & Disclaimer

Expert Advice on MDD Treatment: When to Augment or Switch

Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Rakesh Jain, MD, MPH; Roger McIntyre, MD, FRCPC; and Michael E. Thase, MD, provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in March 2020 and reflects the opinions of the expert panel at that time.

The goal of the tool is to educate clinicians on making optimal management choices advancing treatment in MDD.

A series of questions allow the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include current symptoms, tolerability and adherence to current treatment, and concerns about weight gain, metabolic abnormalities, activation, or sedation. It should be realized that these are not exclusive characteristics when making management choices for patients with MDD. Other considerations that are not included in this tool, such as the presence of various comorbidities, should also be considered, when appropriate.

These recommendations assume that the patient is an adult has a primary diagnosis of MDD without mixed features, and that the patient has had two or more trials of antidepressant monotherapy. 

Based on the characteristics entered, the tool will display experts’ recommendations for that specific patient case.

This program is supported by an educational grant from Otsuka and Lundbeck Alliance.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Leslie Citrome, MD, MPH, Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda; has served on speaker bureaus for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva; and has ownership interest in Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, and Pfizer.

Christoph U. Correll, MD, has disclosed that he has received funds for research support from Janssen/Johnson & Johnson and Takeda; consulting fees from Alkermes, Allergan, Angelini, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/Johnson & Johnson, LB Pharma, Lundbeck, MedAvante-ProPhase, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; fees for non-CME/CE services from Alkermes, Allergan, Angelini, Gedeon Richter, Janssen/Johnson & Johnson, Lundbeck, MedAvante-ProPhase, Otsuka, Pfizer, Recordati, Sumitomo Dainippon, Sunovion, and Takeda.

Rakesh Jain, MD, MPH, has disclosed that he has received consulting fees from Acadia, Alfasigma, Alkermes, Allergan, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Osmotica, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda and Teva; fees from non-CME/CE services from Alkermes, Allergan, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva and Tris Pharmaceuticals; and funds for research support from Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda; and that his spouse/partner has received consulting fees from Lilly, Otsuka, Pamlab, and Sunovion and fees for non-CME/CE services from Lilly.

Roger McIntyre, MD, FRCPC, has disclosed that he has received consulting fees and fees for non-CME/CE services from Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda.

Michael E. Thase, MD, has disclosed that he has received funds for research support from Acadia, Allergan, Axsome, Intracellular, Johnson & Johnson, Otsuka, and Takeda and consulting fees from Acadia, Akili, Alkermes, Allergan, H. Lundbeck, Jazz, Johnson & Johnson, Merck, Otsuka, and Pfizer.

© 2020 Clinical Care Options, LLC. All rights reserved.

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Expert Advice on MDD Treatment: When to Augment or Switch is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices when advancing treatment for MDD. The information provided is based on expert guidance of Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Rakesh Jain, MD, MPH; Roger McIntyre, MD, FRCPC; and Michael E. Thase, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Advice on MDD Treatment: When to Augment or Switch” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.
© 2020 Clinical Care Options, LLC. All rights reserved.

Program Content